(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2007 (11.10.2007)

PCT

(10) International Publication Number
WO 2007/114534 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61P 13/08* (2006.01)

(21) International Application Number:
PCT/KR2006/001242

(22) International Filing Date: 4 April 2006 (04.04.2006)

(25) Filing Language: Korean

(26) Publication Language: English

(71) Applicant *(for all designated States except US)*: **DONG-A PHARMACEUTICAL.CO., LTD.** [KR/KR]; 252 Yongdu-dong Dongdaemun-ku, Seoul 130-072 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YU, Jae Young** [KR/KR]; #944-210 Lotte Apt. Yeongtong-dong, Yeongtong-ku Suwon-si, Kyunggi-do 443-470 (KR). **CHOI, Seul Min** [KR/KR]; #149-1906 Hwanggoljugong Apt., Yeongtong-dong Yeongtong-ku Suwon-si, Kyunggi-do 443-740 (KR). **KANG, Kyung Koo** [KR/KR]; #714-701 Salgugol Donga Apt., Yeongtong-dong Yeongtong-ku Suwon-si, Kyunggi-do 443-736 (KR). **AHN, Byoung Ok** [KR/KR]; #102-201 Baemeuru-mael 555 Yeongmun-ri, Pogok-eup Cheoin-ku Yongin-si, Kyunggi-do 449-813 (KR). **YOO, Moohi** [KR/KR]; #5-801, Woosung 3cha Apt Gaepo-1dong Kangnam-ku, Seoul 135-241 (KR).


(74) Agent: **LEE, Won-Hee**; 8th Fl. Sung-ji Heights Ii 642-16, Yoksam-dong Kangnam-ku, Seoul 135-080 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: AGENT FOR THE PREVENTION AND TREATMENT OF PROSTATIC HYPERPLASIA COMPRISING PYRAZOLOPYRIMIDINONE COMPOUND



(57) Abstract: The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug.

WO 2007/114534 A1

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.